About Von Willebrand Disease — What is VWD
The Humate-P® Difference: High Quality & Quantity
Home Infusion Video
Mix2Vial™ Needle-Free transfer Device

Mix2Vial™ Video
The CSL Behring Commitment
Resources and Tools
News & Events
Important Safety Information
Prescribing Information
Request More Information
For Healthcare Professionals
      

Mix2Vial

Mix2Vial™ is a plastic, needle-free transfer device for use with Humate-P®. For nurses, patients, and parents, the Mix2Vial™ is efficient and convenient, helping to minimize the risk of accidental injury and the time required to prepare Humate-P®.

Mix2Vial™ Benefits:

  • Less risk of accidental injury
  • Less time to prepare product
  • Simple process encourages independence
  • Built-in filter
  • Use with all Luer-Lok® syringes

View a video showing how to mix Humate-P® using Mix2Vial™ Needle-Free Transfer Device.

We encourage you to see the Mix2Vial™ Needle-Free Transfer Device firsthand. Ask your healthcare professional for a demonstration, or call your local CSL Behring representative to find out about events scheduled across the country where you can see how the Mix2Vial™ works.

Request a reusable infusion mat to use when mixing Humate-P®. This colorful instructional mat is designed to be used on your countertop or wherever you infuse. The mat is wipeable, foldable, and convenient for use at home or when you travel.

Contact us at 1-800-504-5434 if you need more information about the Mix2Vial™ Needle-Free Transfer Device.













 

Luer-Lok® is a trademark of Becton, Dickinson and Company.


Did you know that you can self-infuse Humate-P at home using the Mix2Vial?
Watch a video on the 6 steps of self-infusion.


Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see accompanying full prescribing information for Humate-P®.